JP2025148452A5 - - Google Patents

Info

Publication number
JP2025148452A5
JP2025148452A5 JP2025116414A JP2025116414A JP2025148452A5 JP 2025148452 A5 JP2025148452 A5 JP 2025148452A5 JP 2025116414 A JP2025116414 A JP 2025116414A JP 2025116414 A JP2025116414 A JP 2025116414A JP 2025148452 A5 JP2025148452 A5 JP 2025148452A5
Authority
JP
Japan
Prior art keywords
seq
sequence identity
variable region
chain variable
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025116414A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025148452A (ja
Filing date
Publication date
Priority claimed from PCT/CN2022/079021 external-priority patent/WO2023164872A1/en
Priority claimed from PCT/CN2023/079295 external-priority patent/WO2023165561A1/en
Application filed filed Critical
Publication of JP2025148452A publication Critical patent/JP2025148452A/ja
Publication of JP2025148452A5 publication Critical patent/JP2025148452A5/ja
Pending legal-status Critical Current

Links

JP2025116414A 2022-03-03 2025-07-10 抗cd39抗体及びその使用 Pending JP2025148452A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/CN2022/079021 WO2023164872A1 (en) 2022-03-03 2022-03-03 Anti-cd39 antibodies and use thereof
CNPCT/CN2022/079021 2022-03-03
CN2022126070 2022-10-19
CNPCT/CN2022/126070 2022-10-19
PCT/CN2023/079295 WO2023165561A1 (en) 2022-03-03 2023-03-02 Anti-cd39 antibodies and use thereof
JP2024552127A JP7712496B2 (ja) 2022-03-03 2023-03-02 抗cd39抗体及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2024552127A Division JP7712496B2 (ja) 2022-03-03 2023-03-02 抗cd39抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2025148452A JP2025148452A (ja) 2025-10-07
JP2025148452A5 true JP2025148452A5 (cg-RX-API-DMAC7.html) 2026-03-06

Family

ID=87883061

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024552127A Active JP7712496B2 (ja) 2022-03-03 2023-03-02 抗cd39抗体及びその使用
JP2025116414A Pending JP2025148452A (ja) 2022-03-03 2025-07-10 抗cd39抗体及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2024552127A Active JP7712496B2 (ja) 2022-03-03 2023-03-02 抗cd39抗体及びその使用

Country Status (13)

Country Link
US (2) US11970543B2 (cg-RX-API-DMAC7.html)
EP (1) EP4486785A4 (cg-RX-API-DMAC7.html)
JP (2) JP7712496B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240156633A (cg-RX-API-DMAC7.html)
CN (2) CN119173535A (cg-RX-API-DMAC7.html)
AR (1) AR128688A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023227964A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253669A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002620A1 (cg-RX-API-DMAC7.html)
IL (1) IL315351A (cg-RX-API-DMAC7.html)
MX (1) MX2024010646A (cg-RX-API-DMAC7.html)
TW (1) TW202340243A (cg-RX-API-DMAC7.html)
WO (1) WO2023165561A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260191954A1 (en) * 2022-12-01 2026-07-09 Innate Pharma Compositions and methods for neoadjuvant treatment in cancer
CN119798442B (zh) * 2023-12-27 2025-12-16 华润生物医药有限公司 特异性结合cd39的纳米抗体及其用途
WO2026006759A1 (en) 2024-06-28 2026-01-02 Arcus Biosciences, Inc. Pharmaceutical compositions, dosage forms, and methods of making and using same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3153526B1 (en) 2008-01-31 2020-09-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
WO2012085132A1 (en) 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
US10556959B2 (en) * 2014-11-07 2020-02-11 Xencor, Inc. Anti-CD39 antibodies and uses thereof
EP3380519A1 (en) 2015-11-23 2018-10-03 Innate Pharma Cd39 vascular isoform targeting agents
WO2017157948A1 (en) 2016-03-14 2017-09-21 Innate Pharma Anti-cd39 antibodies
US11376269B2 (en) 2016-05-06 2022-07-05 Inserm Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (AML)
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
AU2018235092B2 (en) 2017-03-16 2024-09-19 Innate Pharma Compositions and methods for treating cancer
SG11202000820PA (en) 2017-07-31 2020-02-27 Tizona Therapeutics Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
AU2018346447B2 (en) 2017-10-06 2025-06-19 Innate Pharma Restoration of T cell activity via the CD39/CD73 axis
IL273440B1 (en) 2017-11-15 2026-08-01 Innate Pharma Strengthening the effect of ATP release
CN113754768B (zh) 2018-03-14 2023-01-06 表面肿瘤学公司 结合cd39的抗体及其用途
EP3806902A4 (en) 2018-06-14 2022-05-04 Beth Israel Deaconess Medical Center, Inc. COMPOSITIONS AND METHODS TO PREVENT OR REVERSE T-CELL DEPLETION BY ECTONUCLEOTIDASE INHIBITION AND ANTIBODY-MEDIATED TARGET CYTOSIS
TWI870353B (zh) 2018-06-18 2025-01-21 法商天賜製藥公司 用於治療癌症之組合物及方法
MX2021010119A (es) 2019-02-21 2021-12-10 Trishula Therapeutics Inc Tratamiento combinado con anticuerpos anti-cd39 y anticuerpos anti-pd1 o anti-pd-l1.
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
KR20220050971A (ko) * 2019-08-27 2022-04-25 엘피사이언스 (쑤저우) 바이오파마, 엘티디. 신규 항-cd39 항체
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
CN110407941B (zh) 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
US12391756B2 (en) 2019-11-05 2025-08-19 Jacobio Pharmaceuticals Co., Ltd. Binding molecule specific for CD39 and use thereof
WO2021203058A2 (en) 2020-04-03 2021-10-07 Trishula Therapeutics, Inc. Combination therapy involving anti-cd39 antibodies and adoptive cell therapy
US20240052061A1 (en) 2020-09-10 2024-02-15 Purinomia Biotech, Inc. Methods and compositions for potentiating antitumoral immune responses through targeting of ntpdase3
EP4251650A4 (en) 2020-11-27 2024-10-23 Elpiscience (Suzhou) Biopharma, Ltd. Novel conjugate molecules targeting cd39 and tgfbeta

Similar Documents

Publication Publication Date Title
KR102812377B1 (ko) 인간 폴리오바이러스 수용체(pvr)에 특이적인 항체
KR102757960B1 (ko) 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
JP2023528036A5 (cg-RX-API-DMAC7.html)
KR101453462B1 (ko) Her2에 특이적으로 결합하는 항체
JP2021522801A5 (cg-RX-API-DMAC7.html)
JP2023525827A (ja) 抗cd73抗体およびその使用
JP2018538274A5 (cg-RX-API-DMAC7.html)
JP2014527814A5 (cg-RX-API-DMAC7.html)
JP2018500384A (ja) 腫瘍形成を治療するための治療の組合せ
JP2020527332A5 (cg-RX-API-DMAC7.html)
JP2021533796A5 (cg-RX-API-DMAC7.html)
JP2024016024A5 (cg-RX-API-DMAC7.html)
US20230398229A1 (en) Antibody drug conjugates comprising sting agonists, combinations and methods of use
EA034676B1 (ru) Новое антитело против нетрина-1
US20250042980A1 (en) Complement factor h antibodies
JP2022543658A5 (cg-RX-API-DMAC7.html)
JP2021511387A5 (cg-RX-API-DMAC7.html)
JP2022532991A5 (cg-RX-API-DMAC7.html)
JP2023519807A5 (cg-RX-API-DMAC7.html)
JP2022530241A5 (cg-RX-API-DMAC7.html)
KR20240038769A (ko) 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법
EP3362480B1 (en) Antibody specifically binding to erbb3 and use thereof
JP2024532744A (ja) T1gitアンタゴニスト、pd-1アンタゴニスト、及び(1又は複数の)化学療法剤を含む治療的組合せ
US20260130922A1 (en) Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
US20220389088A1 (en) Anti-angiopoietin-like 4 (angptl4) antibodies and methods of use